• Suspected pancreatic malignancy: Unexplained upper abdominal pain, jaundice, weight loss or new-onset digestive symptoms requiring further investigation.
• Abnormal imaging findings: Pancreatic lesions or structural changes identified on ultrasound, CT or MRI requiring additional assessment.
• Raised tumour markers: Elevated CA 19-9 or other laboratory findings suggesting possible pancreatic pathology.
• High-risk clinical background: Family history of pancreatic cancer, chronic pancreatitis or relevant genetic risk factors.
• Diagnostic support: Clarifying cancer likelihood when conventional testing is inconclusive or delayed.
• Symptom progression: Worsening gastrointestinal or systemic symptoms prompting escalation of investigation.

Overview

Trublood® - Pancreas analyses circulating tumour cells and tumour-derived nucleic material present in peripheral blood. These biomarkers may reflect tumour activity and molecular characteristics relevant to diagnostic evaluation.

Pancreatic malignancy can present with non-specific symptoms or inconclusive imaging findings. In this setting, blood-based tumour biomarker assessment may provide additional support when conventional diagnostic pathways are unclear or invasive tissue sampling is difficult.

Results are interpreted alongside clinical presentation, imaging, tumour markers and specialist assessment. Integrating circulating tumour biomarker findings into the wider diagnostic picture may help guide further investigation or management decisions.

Practical

Specimen

Whole blood 

Container

• 1 x 2 ml SST tube (yellow colour cap) 
• 2 x EDTA tubes (purple colour cap) 
• 1 x 8 ml DCG tube

Volume

17 mL

Patient preparation

The patient must not have received any form of cancer therapy (radiation / chemo-therapy / surgery / endocrine therapy etc.) at least 15 days prior to collection of sample.
The patient must not have received oral or IV corticosteroids at least 15 days prior to collection of sample.
Patient has no current febrile or any other acute inflammatory illness.
Patient does not have acute exacerbation or flare-up of an inflammatory condition requiring escalation in medical therapy at least 5 days prior to collection of sample.
Patient has not received blood transfusion / PET-CT / CT scan at least 5 days prior to collection of sample.
Patient is not positive for HIV / HBV / HCV.